UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2005 (June 27, 2005)


                                 AMPLIDYNE, INC.
             (Exact name of registrant as specified in its charter)


          Delaware                        0-21931                 22-3440510
      (State or Other              (Commission File No.)        (IRS Employer
Jurisdiction of Incorporation)                               Identification No.)


                               59 LaGrange Street
                            Raritan, New Jersey 08869
                     (Address of Principal Executive Office)


                                 (908) 253-6870
               Registrant's telephone number, including area code


      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act



                Section 1 - Registrant's Business and Operations

Item 1.01   Entry into a Material Definitive Agreement.

      On June 27, 2005, the Registrant entered into an agreement with John Chase
Lee, one of the Registrant's  directors,  whereby the Registrant  issued 130,000
shares of Series C preferred stock,  $.0001 par value ("Series C") to Mr. Lee in
satisfaction of loans made by Mr. Lee to the Registrant  totaling  $650,000 (the
"Agreement").  Under the terms of the Agreement  (Exhibit 10.1 attached hereto),
the Registrant will (a) amend the  Certificate of Designations  for the Series C
preferred  stock  to  provide  for a  conversion  rate  of  100  shares  of  the
Registrant's common stock for every one Series C share, among other changes; and
(b) amend the Certificate of Incorporation,  subject to shareholder approval, to
increase the authorized shares of common and preferred stock in order to provide
a sufficient amount of authorized stock to effect the conversion of the Series C
shares held by Mr. Lee. Subsequent to these corporate actions,  Mr. Lee's Series
C shares will be convertible into 13,000,000 shares of common stock.

      As of the date of this Report,  the Registrant  has  17,376,500  shares of
common stock  outstanding.  Subsequent to the above corporate  actions,  Mr. Lee
will hold approximately 42% of the outstanding voting stock of the Registrant.


                   Section 3 - Securities and Trading Markets

Item 3.02.  Unregistered Sales of Equity Securities.

      On June 30,  2005,  the  Registrant  completed  a private  offering of its
common stock,  whereby it raised $150,000 in gross proceeds and issued 5,000,000
shares of its common stock to accredited investors at $.03 per share pursuant to
Regulation D of the Securities Act of 1933, as amended, and Rule 506 promulgated
thereunder.  The  Registrant's  officers  and  directors  directed  the sale and
received no commissions or other remuneration.

      On July 11,  2005,  the  Registrant  completed  a private  offering of its
common stock,  whereby it raised $120,000 in gross proceeds and issued 2,000,000
shares of its common stock to  accredited  investors at $.06 per share  pursuant
Regulation D of the Securities Act of 1933, as amended, and Rule 506 promulgated
thereunder.  The  Registrant's  officers  and  directors  directed  the sale and
received no commissions or other remuneration.


                 Section 5 - Corporate Governance and Management

Item 5.01.  Changes in Control of Registrant.

      See Item 1.01 for a description a description of the  transaction in which
control of the Registrant changed.


Item 5.02.  Departure of Directors or Principal Officers; Election of Directors;
            Appointment of Principal Officers.

      On June 27, 2005,  the  Registrant  accepted the  resignation of Tarlochan
Bains as Chief Executive Officer and President,  and appointed John Chase Lee as
Chairman,  Chief  Executive  Officer  and  President.  On  June  27,  2005,  the
Registrant also appointed  Jessica Lee as Chief Financial  Officer.  Jessica Lee
and John Lee are not related.

      John Chase Lee, age 72, has been a director of the Registrant  since 2004,
and since 2000 has been president of Tek Ltd, a distributor of electronic  parts
for the South Korean auto industry. Mr. Lee has three Masters Degrees, including
M. Div. from Princeton, M.A. from University of Oregon, and an MCRP from Rutgers
University.

      Jessica Lee, age 43, has been  secretary and a director of the  Registrant
since  2004.  Since 1996,  Ms. Lee has owned her own  accounting  firm,  and has
provided accounting and financial services for several New Jersey companies. Ms.
Lee  received a B.A.  from  Yonsei  University,  Seoul,  Korea,  and an MBA from
Rutgers University.

      In 2004, John Lee loaned the Registrant  approximately  $650,000.  On June
27,  2005,  the  Registrant  entered into the  Agreement  described in Item 5.01
above, whereby Mr. Lee was issued 130,000 shares of Series C stock,  convertible
into 13,000,000 shares of common stock, subject to shareholder approval.


                  Section 9 - Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

      (c)   Exhibits.

      10.1  Promissory Note Settlement Agreement dated June 27, 2005.

      99.1  Press Release Dated July 21, 2005.


                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereto duly authorized.

                                           AMPLIDYNE, INC.


Date: July 21, 2005                        By: /s/ John Chase Lee
                                               ---------------------------
                                               John Chase Lee, President